April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
OPTIMA Trial Will Continue to Follow Patients With HCC Treated With ThermoDox Combo
August 5th 2020Patients with hepatocellular carcinoma, or primary liver cancer, treated with ThermoDox plus radiofrequency ablation in the phase 3 OPTIMA clinical trial will continue to be followed for overall survival.
Read More
Data Monitoring Committee Recommends Stopping Phase 3 OPTIMA Trial in Hepatocellular Carcinoma
July 14th 2020The independent Data Monitoring Committee recommended stopping the global phase 3 OPTIMA clinical trial evaluating the combination of ThermoDox with radiofrequency ablation in hepatocellular carcinoma or primary liver cancer.
Read More
HEPANOVA Trial Update: Final Patient With HCC Enrolled to Receive TTFields/Sorafenib
July 9th 2020The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.
Read More
FDA Holds Off on Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC
July 8th 2020The FDA has issued a complete response letter in regard to the applications for potential accelerated approval of pembrolizumab in combination with lenvatinib as treatment of patients with previously untreated, unresectable hepatocellular carcinoma.
Read More
FDA Approves Atezolizumab Combo for Unresectable or Metastatic Hepatocellular Carcinoma
May 29th 2020“For the first-time we have a regimen that markedly improves survival over sorafenib, the standard of care for first-line hepatocellular carcinoma since 2007, and offers patients the opportunity for improved disease control with a favorable tolerability profile.”
Read More
Personalized Treatment for Subtypes of HCC Is the Way of the Future
May 13th 2020In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.
Read More
FDA Grants Orphan Drug Designation to First Liver-Targeted Drug for HCC
May 6th 2020"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."
Read More
Sequencing Targeted Therapies and Immunotherapies in Hepatocellular Carcinoma
April 15th 2020In an interview with Targeted Oncology, Lipika Goyal, MD, discussed the first- and second-line treatment options for patients with hepatocellular carcinoma and shared her thoughts on how these agents should be sequenced.
Read More
Real-Life Analysis of Nivolumab in Patients With HCC Align With Clinical Trial Data
April 7th 2020In an interview with Targeted Oncology, Maria Reig, MD, PhD, discussed the results from the retrospective analysis of patients with hepatocellular carcinoma treated with nivolumab in the real-life setting in Spain.
Read More
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 7th 2020The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Read More
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30th 2020An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
Read More
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
March 30th 2020A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
Read More
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
March 23rd 2020In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Read More
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
March 21st 2020Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Read More
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20th 2020Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
Read More
Optimizing Treatment Approaches for Hepatocellular Carcinoma
March 10th 2020David J. Pinato, MD, PhD, discusses the importance of utilizing a multidisciplinary approach when treating patients with hepatocellular carcinoma and how this approach helps optimize patient outcomes now as well as how it will help in the near future as more therapies emerge.
Watch
Bevacizumab Biosimilar Under Review by FDA
March 9th 2020The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.
Read More